Catalyst overview
Research summary
This catalyst tracks a Phase 1a data readout for TX2100 in Hereditary Hemorrhagic Telangiectasia (HHT). The expected timing is based on the latest available company guidance and may change.
8/7/25- Initiate trial in Q1 2026. 02/26/26:- First subject randomized in Phase 1a HV trial in February 2026; topline results expected in Q4 2026. 05/07/26:- Phase 1a HV trial dosed four cohorts; topline results expected Q3 2026; Phase 2 PoC planned early 2027. 08/06/26:- Ph1a dosing completed; topline results expected Q3 2026; Ph1b and Ph2 planned Early 2027.
Verification
Confirm timing and program details against the company announcement or filing.